Gracell Biotechnologies Doses First Patient In Phase 1b/2 Clinical Trial In U.S. Evaluating GC012F For Treatment Of Relapsed/Refractory Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Gracell Biotechnologies has dosed the first patient in a Phase 1b/2 clinical trial in the U.S. for its lead candidate, GC012F, for the treatment of relapsed or refractory multiple myeloma (RRMM). The trial will evaluate the safety, tolerability, and efficacy of GC012F, which is developed on the proprietary FasTCAR next-day manufacturing platform. GC012F has shown promising results in prior clinical studies, with a 93.1% overall response rate among high-risk RRMM patients.
September 26, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gracell Biotechnologies has initiated a Phase 1b/2 clinical trial for GC012F, a treatment for RRMM. The trial will evaluate the safety and efficacy of GC012F, which has shown promising results in prior studies.
The initiation of the Phase 1b/2 clinical trial for GC012F is a significant step for Gracell Biotechnologies. If the trial results are positive, it could lead to regulatory approval and commercialization of GC012F, which would be a significant revenue driver for the company. The promising results from prior studies also increase the likelihood of positive outcomes from this trial.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100